A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: A novel approach by using meta-regression

Oncology (Switzerland)

Volumn 82, Issue 5, 2012, Pages 275-289

  Shen, Ying Chun ^a   Hsu, Chiun ^b   Cheng, Chia Chi ^b   Hu, Fu Chang ^b   Cheng, Ann Lii ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antiviral therapy; Chronic hepatitis B; Chronic hepatitis C; Hepatocellular carcinoma

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; HEPATITIS E ANTIGEN; INTERFERON; LAMIVUDINE; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CLINICAL RESEARCH; DISEASE ASSOCIATION; DRUG EFFICACY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; META ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84860593438     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000337293     Document Type: Article

References (54)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS: Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101: 1348-1355.
3. Mendy ME, Welzel T, Lesi OA, Hainaut P, Hall AJ, Kuniholm MH, McConkey S, Goedert JJ, Kaye S, Rowland-Jones S, Whittle H, Kirk GD: Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in the Gambia, West Africa. J Viral Hep 2010; 17: 115-122.
4. Pomper GJ, Wu Y, Snyder EL: Risks of transfusion-transmitted infections. Curr Opin Hematol 2003; 10: 412-418.
5. Camma C, Giunta M, Andreone P, Craxi A: Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidencebased approach. J Hepatol 2001; 34: 593-602. (Pubitemid 32328518)
6. Camma C, Di Bona D, Crax A: The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. Curr Pharm Des 2004; 10: 2123-2130. (Pubitemid 38842656)
7. Cammà C, Licata A, Cabibbo G, Latteri F, Craxì A: Treatment of hepatitis C: critical appraisal of the evidence. Expert Opin Pharmacother 2005; 6: 399-408. (Pubitemid 40521077)
8. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK: Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 192-199.
9. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL: Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-1077.
10. Miyake Y, Kobashi H, Yamamoto K: Metaanalysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol 2009; 44: 470-475.
11. Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N: Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009; 16: 265-271.
12. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Müllhaupt B, Clavien PA: Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009; 96: 975-981.
13. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL: Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol 2010; 52: 889-894.
14. Thompson SG, Higgins JP: Can meta-analysis help target interventions at individuals most likely to benefit? Lancet 2005; 365: 341-346. (Pubitemid 40139113)
15. Sherman M: Hepatitis C and hepatocellular carcinoma: grist for the mill. Gastroenterology 2009; 136: 39-42.
16. Simmonds MC, Higgins JPT: Covariate heterogeneity in meta-analysis: criteria for deciding between meta-regression and individual patient data. Stat Med 2007; 26: 2982-2999. (Pubitemid 46939422)
17. Baker WL, White CM, Cappelleri JC, Kluger J, Coleman CI: Understanding heterogeneity in meta-analysis: the role of meta-regression. Int J Clin Pract 2009; 63: 10: 1426-1434.
18. Hsu C, Shen YC, Cheng CC, Hu FC, Cheng AL: Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. Contemp Clin Trials 2010; 31: 55-61.
19. Egger M, Davey-Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a single, graphical test. BMJ 1997; 315: 629-634. (Pubitemid 27387172)
20. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, Bourliere M, Boucher E, Miguet JP, Parlier D, Lemonnier C, Opolon P: Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999; 29: 1870-1875. (Pubitemid 29247063)
21. Azzaroli F, Accogli E, Nigro G, Trere D, Giovanelli S, Miracolo A, Lodato F, Montagnani M, Tamé M, Colecchia A, Mwangemi C, Festi D, Roda E, Derenzini M, Mazzella G: Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. World J Gastroenterol 2004; 10: 3099-3102. (Pubitemid 39419866)
22. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S: Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
23. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, Habu D, Tanaka T: Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001; 357: 196-197. (Pubitemid 32108094)
24. Soga K, Shibasaki K, Aoyagi Y: Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatogastroenterology 2005; 52: 1154-1158. (Pubitemid 40942206)
25. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Novelli V, Cipolla A, Fabbri C, Pezzoli A, Roda E: Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24: 141-147. (Pubitemid 26057950)
26. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, Almasio P, Solinas A, Brouwer JT, Thomas H, Realdi G, Corrocher R, Schalm SW: Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997; 27: 201-205. (Pubitemid 27357077)
27. International Interferon-alpha Hepatocellular Carcinoma Study Group: Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 351: 1535-1539.
28. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A: Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998; 83: 901-909. (Pubitemid 28401923)
29. Gramenzi A, Andreone P, Fiorino S, Cammà C, Giunta M, Magalotti D, Cursaro C, Calabrese C, Arienti V, Rossi C, Di Febo G, Zoli M, Craxì A, Gasbarrini G, Bernardi M: Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001; 48: 843-848. (Pubitemid 32476987)
30. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y: Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Int Med 1998; 129: 94-99. (Pubitemid 28337250)
31. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, Nishioji K, Murakami Y, Kashima K: Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1,148 patients. J Hepatol 1999; 30: 653-659. (Pubitemid 29151907)
32. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Int Med 1999; 131: 174-181. (Pubitemid 29364999)
33. Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, Kanda T, Kashiwagi T, Inoue A, Kato M, Oshima A, Kinoshita Y, Kamada T: Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000; 87: 741-749. (Pubitemid 30620419)
34. Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Arase Y, Murashima N, Chayama K, Kumada H: Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study. J Gastroenterol Hepatol 2001; 16: 406-415. (Pubitemid 32397653)
35. Shiratoni Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, Arakawa Y, Hashimoto E, Hirota K, Yoshida H, Ohashi Y, Omata M: Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Int Med 2005; 142: 105-114.
36. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Someya T, Hosaka T, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Kumada H: Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center. Intervirology 2006; 49: 82-90. (Pubitemid 41318181)
37. Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF: A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006; 11: 985-994.
38. Liaw YF, Sung JJY, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J: Lamivudine for patients with chronic hepatitis B and advanced liver disease. New Eng J Med 2004; 351: 1521-1531.
39. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW: Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 1997; 26: 1338-1342. (Pubitemid 27509322)
40. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Fukuda M, Koida I, Arase Y, Chayama K, Murashima N, Kumada H: Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 1998; 82: 827-835. (Pubitemid 28104160)
41. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, Okita K, Hayashi N, Okanoue T, Iino S, Tanikawa K: Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2,795 patients. Hepatol Res 2005; 32: 173-184. (Pubitemid 41078655)
42. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF: Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 45-52.
43. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200-207. (Pubitemid 36169630)
44. Schmid CH, Stark PC, Berlin JA, Landais P, Lau J: Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J Clin Epidemiol 2004; 57: 683-697. (Pubitemid 39195218)
45. Lambert PC, Sutton AJ, Abrams KR, Jones DR: A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol 2002; 55: 86-94. (Pubitemid 34037039)
46. Dancey JE, Dodd LE, Ford R, Kaplan R, Mooney M, Rubinstein L, Schwartz LH, Shankar L, Therasse P: Recommendations for the assessment of progression in randomized cancer treatment trials. Eur J Cancer 2009; 45: 281-289.
47. Hung CH, Lee CM, Lu SN, Wang JH, Hu TH, Tung HD, Chen CH, Chen WJ, Changchien CS: Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat 2006; 13: 409-414.
48. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Fagiuoli S, Almasio PL: Sustained virological response to interferon-is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587. (Pubitemid 46453759)
49. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM: Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49: 729-738.
50. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, Rizzetto M, Craxi A: Clinical Outcome of HBeAgnegative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883-891. (Pubitemid 39288121)
51. Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikolou I, Manesis EK: Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET -Greece cohort study. Gut 2011; 60: 1109-1116.
52. Liaw YF: Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009; 29(suppl 1): 100-107.
53. Chen CJ, Yang HI, Su I, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. (Pubitemid 43042691)
54. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN, You SL, Chen DS, Liaw YF, Chen CJ: Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 1134-1143.